ObjectiveMany people want to have healthy facial skin. They tend to check their skin’s condition by touching their face with their hands. In the cosmetic industry, we need to understand what consumers are perceiving in a tactile sense when touching their own facial skin. The purpose of this study was to investigate these observation methods in order to systematically understand people’s haptic exploratory procedures (HEPs).MethodsThirty‐four participants living in the United States and twenty‐two participants living in Japan freely explored their faces and answered which side felt more closely related to the six tactile adjectives. A new analysis was applied to classify the observed HEPs into six classifications within two categories and three sizes of contact area by experts.ResultIt was confirmed that the new task was useful to observe the HEPs for participants from United States and Japan. The US participants’ HEPs for ‘moisturized’ were mainly a middle‐sized contact area using a stroking motion. On the other hand, Japanese participants’ HEPs for ‘moisturized’ (‘shittori’ in Japanese) mainly used a pushing movement. Moreover, the US participants’ HEPs for ‘soft’ included both pushing and stroking, but Japanese participants HEPs for ‘soft’ (‘yawarakai’ in Japanese) were again mainly pushing.ConclusionThis study suggests that the proposed analysis method enables the systematic understanding of HEPs when checking the skin, along with the cross‐cultural differences affecting those procedures. These systematic findings could allow cosmetic formulators to have a better understanding of the tactile sensations consumers themselves are feeling in a variety of different global markets.

In typical kinase inhibitor programs, a hinge binder showing best potency with preferential specificity is initially selected, followed by fine-tuning of the accompanying substituents on its core module. A shortcoming of this approach is that the exclusive focus on a single chemotype can endanger all the analogues in the series if a critical shortcoming is revealed. Thus, an early evaluation of structure−activity relationships (SARs) can mitigate unforeseen outcomes within a series of multiple compounds, although there have been very few examples to follow such a policy. PI4KIIIα is one of four mammalian phosphatidylinositol-4 kinases and has recently drawn significant attention as an emerging target for hepatitis C virus (HCV) treatment. In this letter, a novel "head-to-tail" approach to discover a diverse set of PI4KIIIα inhibitors is reported. We believe this method will generate distinct core scaffolds, a rational strategy to circumvent potential risks in general kinase programs.